Comparing the Effects of Cognitive and Physical Training on Cognitive Function and Brain Activation in People With Mild Cognitive Impairment and Mild Dementia: A Randomized Controlled Trial.

Arch Phys Med RehabilMay 2, 2026 (epub)
Clinical ResearchGeriatricsNeurology

Wei-Han Weng, Yea-Ru Yang, Yin-Hsiang Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effects of cognitive training (CT) and physical training (PT) on cognitive function and brain activation in older adults with mild cognitive impairment or mild dementia. Both interventions showed cognitive benefits, but PT significantly improved ADAS-Cog scores compared to the control group, with a P-value of .008. Additionally, CT resulted in decreased prefrontal cortex activation.

Key findings

  • CTG improved ADAS-Cog scores compared to CG (P=.022).
  • PTG exceeded the minimal clinically important difference on the ADAS-Cog.
  • CTG showed decreased PFC activation compared to CG and PTG (P=.002 vs PTG).
  • PTG improved timed Up and Go performance compared to CG (P=.046).

Why it matters

Understanding the differential impacts of cognitive and physical training on cognitive function can guide interventions for older adults with cognitive impairments, potentially enhancing their quality of life and functional independence.

Source

PubMed · PMID 42081986

Published in Arch Phys Med Rehabil. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.